Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent

Anticancer Research

Volumn 29, Issue 8, 2009, Pages 2961-2969

  Vaziri, Susan A J ^a   Grabowski, Dale R ^a   Hill, Jason ^a   Rybicki, Lisa R ^a   Burk, Robert ^b   Bukowski, Ronald M ^a   Ganapathi, Mahrukh K ^a   Ganapathi, Ram ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Bortezomib; p53; Proteasome; Renal cancer; VHL

Indexed keywords

BORTEZOMIB; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN P21; PROTEIN P53; SMALL INTERFERING RNA; SURVIVIN; VON HIPPEL LINDAU PROTEIN;

ARTICLE; CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXICITY; DNA METHYLATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; KIDNEY CANCER; KIDNEY CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; VHL GENE;

APOPTOSIS; BORONIC ACIDS; CARCINOMA, RENAL CELL; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA METHYLATION; GENE EXPRESSION PROFILING; HUMANS; KIDNEY NEOPLASMS; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 68549094348     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. ACS. (2007). American Cancer Society: Atlanta.
2. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R and Bukowski RM; TARGET Study Group: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356: 125-134, 2007. (Pubitemid 46089673)
3. Motzer RJ, Mazumdar M, Bacik J, Russo P, Berg WJ and Metz EM: Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 18: 1928-1935, 2000.
4. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX AND Rosenberg SA: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349: 427-434, 2003. (Pubitemid 36910021)
5. Cockman ME, Masson N, Mole DR, Jaakkola P, Chang GW, Clifford SC, Maher ER, Pugh CW, Ratcliffe PJ and Maxwell PH: Hypoxia-inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 275: 25733-25741, 2000. (Pubitemid 30687077)
6. Linehan WM, Walther MM Zbar B: The genetic basis of cancer of the kidney. J Urol 170: 2163-2172, 2003.
7. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER and Ratcliffe PJ: The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399: 271-275, 1999.
8. Devarajan P, De Leon M, Talasazan F, Schoenfeld AR, Davidowitz EJ and Burk RD: The von Hippel-Lindau gene product inhibits renal cell apoptosis via Bcl-2-dependent pathways. J Biol Chem 276: 40599-40605, 2001. (Pubitemid 37373200)
9. Qi H and Ohh M: The von Hippel-Lindau tumor suppressor protein sensitizes renal cell carcinoma cells to tumor necrosis factor-induced cytotoxicity by suppressing the nuclear factor-κB-dependent antiapoptotic pathway. Cancer Res 63: 7076-7080, 2003. (Pubitemid 37413442)
10. Schoenfeld AR, Parris T, Eisenberger A, Davidowitz EJ, De Leon M, Talasazan F, Devarajan P and Burk RD: The von Hippel-Lindau tumor suppressor gene protects cells from UV-mediated apoptosis. Oncogene 19: 5851-5857, 2000. (Pubitemid 32005365)
11. Richardson PG, Mitsiades C, Hideshima T and Anderson KC: Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med 57: 33-47, 2006. (Pubitemid 43261977)
12. WAF1/CIP1 expression. Biochem Biophys Res Commun 227: 564-569, 1996.
13. Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, Tsang BK and Cheng JQ: Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J Biol Chem 279: 5405-5412, 2004. (Pubitemid 38220563)
14. Hu X, Bryington M, Fisher AB, Liang X, Zhang X, Cui D, Datta I and Zuckerman KS: Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest. J Biol Chem 277: 16528-16537, 2002. (Pubitemid 34967668)
15. Kip1 by ubiquitination. Proc Natl Acad Sci USA 97: 4579-4584, 2000. (Pubitemid 30238600)
16. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J and Baldwin AS Jr: Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappa;B inhibition. Cancer Res 61: 3535-3540, 2001. (Pubitemid 32694955)
17. 2-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9: 1145-1154, 2003. (Pubitemid 36323724)
18. Teicher BA, Ara G, Herbst R, Palombella VJ and Adams J: The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 5: 2638-2645, 1999. (Pubitemid 29437352)
19. Dai Y, Rahmani M and Grant S: Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-kappaB-dependent process. Oncogene 22: 7108-7122, 2003. (Pubitemid 37378543)
20. Van Waes C, Chang AA, Lebowitz PF, Druzgal CH, Chen Z, Elsayed YA, Sunwoo JB, Rudy SF, Morris JC, Mitchell JB, Camphausen K, Gius D, Adams J, Sausville EA and Conley BA: Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 63: 1400-1412, 2005. (Pubitemid 41628035)
21. Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi, MK, Ganapathi R and Mekhail T: Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-κKB-independent mechanisms. Anticancer Res 26: 1869-1876, 2006.
22. Vaziri SA, Hill J, Chikamori K, Grabowski DR, Takigawa N, Chawla-Sarkar M, Rybicki LR, Gudkov AV, Mekhail T, Bukowski RM, Ganapathi MK and Ganapathi R: Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3σ and survivin. Mol Cancer Ther 4: 1880-1890, 2005.
23. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, Niesvizky R, Alexanian R, Limentani SA, Alsina M, Adams J, Kauffman M, Esseltine DL, Schenkein DP and Anderson KC: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 127: 165-172, 2004. (Pubitemid 39371809)
24. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, Fayad L, Dang NH, Samaniego F, Wang M, Broglio K, Samuels B, Gilles F, Sarris AH, Hart S, Trehu E, Schenkein D, Cabanillas F and Rodriguez AM: Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23: 667-675, 2005. (Pubitemid 46224166)
25. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, Straus D, Portlock C, Hamlin P, Choi E, Dumetrescu O, Esseltine D, Trehu E, Adams J, Schenkein D and Zelenetz AD: Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23: 676-684, 2005. (Pubitemid 46237441)
26. Scagliotti, G: Proteasome inhibitors in lung cancer. Crit Rev Oncol Hematol 58: 177-189, 2006.
27. Dreicer R, Petrylak D, Agus D, Webb I and Roth B: Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin Cancer Res 13: 1208-1215, 2007. (Pubitemid 46424062)
28. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ and Stadler WM: Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 22: 115-119, 2004. (Pubitemid 41095122)
29. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, Mazumdar M and Motzer RJ: Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 22: 3720-3725, 2004. (Pubitemid 41095212)
30. Ciechanover A: The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17: 7151-7160, 1998. (Pubitemid 29002684)
31. Hoffman WH, Biade S, Zilfou JT, Chen J and Murphy M: Transcriptional repression of the anti-apoptotic survivin gene by wild-type p53. J Biol Chem 277: 3247-3257, 2002. (Pubitemid 34953189)
32. Dohi T, Beltrami E, Wall NR, Plescia J and Altieri DC: Mitochondrial surviving inhibits apoptosis and promotes tumorigenesis. J Clin Invest 114: 1117-1127, 2004. (Pubitemid 39578701)
33. Shankar SL, Mani S, O'Guin KN, Kandimalla ER, Agrawal S and Shafit-Zagardo B: Survivin inhibition induces human neural tumor cell death through caspase-independent and -dependent pathways. J Neurochem 79: 426-436, 2001. (Pubitemid 32988959)
34. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, Kawashima T, Nanakin A, Sawabu T, Uenoyama Y, Sekikawa A, Kawada M, Suzuki K, Kayahara T, Fukui H, Sawada M and Chiba T: STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 23: 4921-4929, 2004. (Pubitemid 38932164)
35. Brummelkamp TR, Bernards R and Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 296: 550-553, 2002. (Pubitemid 34408678)
36. Tabata M, Tabata R, Grabowski DR, Bukowski RM, Ganapathi MK and Ganapathi R: Roles of NF-κB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human non-small cell lung carcinoma. J Biol Chem 276: 8029-8036, 2001. (Pubitemid 37385604)
37. Janezic SA, Ziogas A, Krumroy LM, Krasner M, Plummer SJ, Cohen P, Gildea M, Barker D, Haile R, Casey G and Anton-Culver H: Germline BRCA1 alterations in a population-based series of ovarian cancer cases. Hum Mol Genet 8: 889-897, 1999. (Pubitemid 29189057)
38. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996. (Pubitemid 26296693)
39. Frevel MA, Bakheet T, Silva AM, Hissong JG, Khabar KS and Williams BR: p38 Mitogen-activated protein kinase-dependent and -independent signaling of mRNA stability of AU-rich element-containing transcripts. Mol Cell Biol 23: 425-436, 2003. (Pubitemid 36050538)
40. Mirza A, McGuirk M, Hockenberry TN, Wu Q, Ashar H, Black S, Wen SF, Wang L, Kirschmeier P, Bishop WR, Nielsen LL, Pickett CB and Liu S: Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 21: 2613-2622, 2002. (Pubitemid 34478319)
41. An J, Fisher M and Rettig MB: VHL expression in renal cell carcinoma sensitizes to bortezomib (PS-341) through an NF-κB-dependent mechanism. Oncogene 24: 1563-1570, 2005.
42. Gurova KV, Hill JE, Guo C, Prokvolit A, Burdelya LG, Samoylova E, Khodyakova AV, Ganapathi R, Ganapathi M, Tararova ND, Bosykh D, Lvovskiy D, Webb TR, Stark GR and Gudkov AV: Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors. Proc Natl Acad Sci USA 102: 17448-17453, 2005. (Pubitemid 41740886)